Clinical trials: Biliary Tract Adenocarcinoma
Gallstone, Cholangitis
Evaluation of MRI Sequences for Ultra-rapid Acquisition of Bile Ducts Images
The Institute of Imaged-Guided Surgery (IHU Strasbourg) has two clinical Magnetic Resonance Imaging (MRI) scanners, one with a 3T (3 Teslas) magnetic field used for diagnosis, the other with a magnetic field of 1,5T (1,5 Teslas)…
- Conditions
- Gallstone, Cholangitis, Cholangiocarcinoma, Pancreatitis
- Trial name
- BiliFast (NCT03852836)
- Testing
- ultra-rapid acquisition of bile ducts images
- Where
- France
- Volunteers
- 53 people
- Sponsor
- IHU Strasbourg
Cholangiocarcinoma, Choledocholithiasis; Cholangitis
Efficacy of Fistulotomy for Biliary Cannulation
Access to the main bile duct is the first step in order to perform a therapeutic maneuver for biliary diseases. Early precut has been shown to ameliorate cannulation success rate, specially in difficult cannulation cases, when…
- Conditions
- Cholangiocarcinoma, Choledocholithiasis; Cholangitis, Pancreatic Cancer, Pancreatitis
- Trial name
- NCT04037007
- Testing
- Fistulotomy - High experienced., Fistulotomy - Low experienced., Conventional (guidewire) cannulation- High experienced
- Where
- Mexico
- Volunteers
- 320 people
- Sponsor
- Coordinación de Investigación en Salud, Mexico
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer, Pancreatic Cancer
- Trial name
- NCT00987766
- Testing
- erlotinib hydrochloride, gemcitabine hydrochloride, oxaliplatin
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Cholangiocarcinoma, Malignant Digestive System Neoplasm
Molecular Epidemiology of Biliary Tree Cancers
This study is to learn if certain risk factors (environmental, viral, behavioral, medical, and dietary), tumor markers, and genetic changes can predict the development and outcome of biliary tree cancers.
- Trial name
- NCT05179486
- Testing
- Biospecimen Collection, Questionnaire Administration
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- M.D. Anderson Cancer Center
Biliary Tract Cancer
ctDNA Detection of MRD in Predicting Postoperative Recurrence in Biliary Tract Cancers：A Multicenter Prospective Trial
A substantial proporation of patients with biliary tract malignancies still experience disease recurrence after curative resection.
- Trial name
- NCT05743959
- Testing
- No intervention
- Where
- China
- Volunteers
- 100 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Cholangitis
Best Biliary Drainage Option in Advanced Klatskin Tumor
To investigate the biliary drainage-related cholangitis and other complications of percutaneous transhepatic biliary drainage (PTBD) in the management of Klatskin tumor (KT) compared with endoscopic biliary drainage (EBD).
- Trial name
- NCT03104582
- Testing
- ERCP Drainage, PTBD Drainage
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Hepatopancreatobiliary Surgery Institute of Gansu Province
Cholangiocarcinoma, Gallbladder Carcinoma
Clinical Trial to Investigate the Efficacy of Treatment With Gemcitabine/Pazopanib in Patients With Biliary Tree Cancer
The purpose of this study is to determine whether gemcitabine and pazopanib are effective in the treatment of inoperable, locally advanced or metastatic biliary tree cancer (cholangiocarcinoma or gallbladder carcinoma).
- Conditions
- Cholangiocarcinoma, Gallbladder Carcinoma, Biliary Carcinoma
- Trial name
- NCT01855724
- Testing
- Gemcitabine-Pazopanib
- Where
- 17 sites in Greece
- Volunteers
- 29 people
- Sponsor
- Hellenic Cooperative Oncology Group
Biliary Tract Cancer, Gallbladder Adenocarcinoma
Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer
The main purpose of this study is to test the safety and effectiveness of oxaliplatin, bevacizumab, and capecitabine given in combination with radiation therapy to see what effects (good or bad) they have on patients with biliary…
- Trial name
- NCT00142480
- Testing
- Capecitabine, Oxaliplatin, Bevacizumab
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- Massachusetts General Hospital
Locally Advanced Malignant Solid Neoplasm, Locally Advanced Unresectable Cholangiocarcinoma
Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies
This phase I/II trial studies the best dose and side effects of peposertib and to see how well it works with avelumab and hypofractionated radiation therapy in treating patients with solid tumors and hepatobiliary malignancies…
- Conditions
- Locally Advanced Malignant Solid Neoplasm, Locally Advanced Unresectable Cholangiocarcinoma, Locally Advanced Unresectable Gallbladder Carcinoma, Locally Advanced Unresectable Malignant Solid Neoplasm
- Trial name
- NCT04068194
- Testing
- Avelumab, Biopsy Procedure, Biospecimen Collection
- Where
- 46 sites in United States
- Volunteers
- 103 people
- Sponsor
- National Cancer Institute (NCI)
Primary Sclerosing Cholangitis, Trisomy 7
Erlotinib for Chemoprevention in Trisomy 7 Positive Primary Sclerosing Cholangitis (PSC)
Primary sclerosing cholangitis (PSC) is a chronic inflammatory condition of the bile ducts of unknown etiology. It is characterized by diffuse inflammation and stricturing of the entire biliary tree, eventually resulting in…
- Conditions
- Primary Sclerosing Cholangitis, Trisomy 7, Cholangiocarcinoma, Chemoprevention
- Trial name
- NCT00955149
- Testing
- Erlotinib (Tarceva)
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Mayo Clinic
Cancer
Aminocamptothecin in Treating Patients With Advanced Cancer of the Peritoneal Cavity
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of aminocamptothecin in treating patients with advanced…
- Trial name
- NCT00003548
- Testing
- aminocamptothecin colloidal dispersion
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- NYU Langone Health
Biliary Tract Neoplasms, Advanced Cancer
A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer
"Biliary tract cancer (BTC) is a rare malignancy with a poor prognosis. Most patients present with unresectable disease, and even after curative-intent resection, recurrence is common.
- Conditions
- Biliary Tract Neoplasms, Advanced Cancer, Immunotherapy
- Trial name
- NCT07269158
- Testing
- Durvalumab or Pembrolizumab, Durvalumab or Pembrolizumab + Levnatinib, Durvalumab or Pembrolizumab + Venadaparib
- Where
- South Korea
- Volunteers
- 160 people
- Sponsor
- Yonsei University
Urothelial Bladder Cancer, Gastric Adenocarcinoma
Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab
Treatment will consist of a PARP inhibitor (niraparib) monotherapy priming period (cycle 0; 21 days); an anti-PD-1 antibody (Dostarlimab ; TSR-042) will then be added from C1D1 every 21 days in combination for the first 4 cycles…
- Conditions
- Urothelial Bladder Cancer, Gastric Adenocarcinoma, Gastro-oesophageal Adenocarcinoma, Head and Neck Cancer
- Trial name
- NIRADO (NCT04779151)
- Testing
- Dostarlimab, Niraparib
- Where
- France
- Volunteers
- 51 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Acinar Cell Carcinoma, Adenoid Cystic Carcinoma
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may…
- Conditions
- Acinar Cell Carcinoma, Adenoid Cystic Carcinoma, Adrenal Cortical Carcinoma, Adrenal Gland Pheochromocytoma
- Trial name
- NCT02834013
- Testing
- Biospecimen Collection, Computed Tomography, Echocardiography Test
- Where
- 1,007 sites in United States, Guam
- Volunteers
- 798 people
- Sponsor
- National Cancer Institute (NCI)
Primary Sclerosing Cholangitis (PSC)
Cholangioscopy in Primary Sclerosing Cholangitis (PSC)
To demonstrate the clinical utility of the addition of per oral cholangioscopy (POCS) to standard endoscopic retrograde cholangiopancreatography (ERCP) with brushing cytology for diagnosis and early detection of…
- Trial name
- NCT03766035
- Testing
- SpyGlass DS I - II
- Where
- 6 sites in United States, Canada and 2 more
- Volunteers
- 43 people
- Sponsor
- Boston Scientific Corporation
Cholangiocarcinoma, Biliary Tract Cancer
Trastuzumab in HER2-positive Biliary Tract Cancer
Trastuzumab is approved for the treatment of HER2-positive breast cancer and gastric cancer. The recent study showed that HER2 overexpression or amplification is noted about 5-15% of total biliary tract cancer patients.
- Conditions
- Cholangiocarcinoma, Biliary Tract Cancer, HER-2 Protein Overexpression, HER-2 Gene Amplification
- Trial name
- BILHER (NCT03613168)
- Testing
- Trastuzumab
- Where
- South Korea
- Volunteers
- 4 people
- Sponsor
- Changhoon Yoo
Bile Duct Adenocarcinoma, Bile Duct Carcinoma
Study of Large Channel Digital Pancreaticobiliary Scope (DPS) With Compatible Accessories
This study plans to enroll up to 75 research subject who have a biliary disorder such as bile duct stones or intermediate biliary strictures.
- Trial name
- NCT07120295
- Testing
- Dragonfly™ Digital Pancreaticobiliary System
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of Colorado, Denver
Hilar Cholangiocarcinoma, Primary Sclerosing Cholangitis
Liver Transplantation for Hilar Cholangiocarcinoma in Association With Neoadjuvant Radio- and Chemo-therapy
Single-arm pilot clinical trial. Patients with non operable CC associated with PSC will be subjected to liver transplantation after a neoadjuvant multimodal therapy protocol.
- Trial name
- NCT01549795
- Testing
- Liver transplantation, 45 Gy external radiations, Endoluminal bile duct Brachytherapy
- Where
- Italy
- Volunteers
- 33 people
- Sponsor
- Azienda Ospedaliera di Padova
Carcinoma of Intrahepatic and Extra-hepatic Biliary System, Carcinoma of Gallbladder
Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder
DKN-01 is a humanized monoclonal antibody (Mab) with neutralizing activity against Dkk-1 and is being developed as an anti-neoplastic agent.
- Conditions
- Carcinoma of Intrahepatic and Extra-hepatic Biliary System, Carcinoma of Gallbladder, Bile Duct Cancer, Cholangiocarcinoma
- Trial name
- NCT02375880
- Testing
- DKN-01, gemcitabine, cisplatin
- Where
- 9 sites in United States
- Volunteers
- 51 people
- Sponsor
- Leap Therapeutics, Inc.
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
This phase I trial is studying the side effects and best dose of erlotinib hydrochloride when given together with cetuximab and to see how well they work in treating patients with advanced gastrointestinal cancer, head and neck…
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
- Trial name
- NCT00397384
- Testing
- cetuximab, erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- National Cancer Institute (NCI)